Implantable eye telescope approved for use in patients
Page 1 of 1 • Share
Implantable eye telescope approved for use in patients
[You must be registered and logged in to see this image.]
NEW YORK: A miniature telescope that is implanted in the eye to solve sight problems has been approved for use in the US.
The new device is for people with an irreversible, advanced form of macular degeneration in which a blind spot develops in the central vision of both eyes.
The telescope replaces the eye’s nature lens and can provide an image that is magnified by almost three times.
The device then magnifies and projects the images onto a healthy portion of the retina.
The firm behind the telescope claims that it will help patients suffering from end-stage age-related macular degeneration (AMD), a disease which is the leading cause of vision loss in the US.
It can only be used in one eye because the other is needed for peripheral vision.
Patients who receive the telescope will need rehabilitation to help retrain their brain to merge the views from the two eyes into a single image.
It is intended for patients 75 and older with severe vision impairment caused by blind spots and clinical tests found that for 75 per cent saw an improvement in their eyesight.
The drugs watchdog, the FDA, said that the telescope’s size might mean that patients will also need a corneal transplant after the operation.
Wet AMD is caused by abnormal growth of blood vessels around the eye, and can be treated by stopping the growth of a natural protein called vascular endothelial growth factor (VEGF).
The firm behind the telescope, VisionCare, must now carry out two further studies, following up existing patients and beginning a study of 770 new patients.
Each telescope will cost $15,000.
NEW YORK: A miniature telescope that is implanted in the eye to solve sight problems has been approved for use in the US.
The new device is for people with an irreversible, advanced form of macular degeneration in which a blind spot develops in the central vision of both eyes.
The telescope replaces the eye’s nature lens and can provide an image that is magnified by almost three times.
The device then magnifies and projects the images onto a healthy portion of the retina.
The firm behind the telescope claims that it will help patients suffering from end-stage age-related macular degeneration (AMD), a disease which is the leading cause of vision loss in the US.
It can only be used in one eye because the other is needed for peripheral vision.
Patients who receive the telescope will need rehabilitation to help retrain their brain to merge the views from the two eyes into a single image.
It is intended for patients 75 and older with severe vision impairment caused by blind spots and clinical tests found that for 75 per cent saw an improvement in their eyesight.
The drugs watchdog, the FDA, said that the telescope’s size might mean that patients will also need a corneal transplant after the operation.
Wet AMD is caused by abnormal growth of blood vessels around the eye, and can be treated by stopping the growth of a natural protein called vascular endothelial growth factor (VEGF).
The firm behind the telescope, VisionCare, must now carry out two further studies, following up existing patients and beginning a study of 770 new patients.
Each telescope will cost $15,000.
Zeba Khan Hoti- Monstars
- Posts : 773
Join date : 2011-02-24
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Yesterday at 10:16 pm by ali001
» Amuse - Become Smarter
Wed May 15, 2024 10:50 am by ali001
» Fort Lock
Sat May 04, 2024 11:49 am by ali001
» house disrepair claims
Thu May 02, 2024 4:29 pm by Ibad Khan Buledi
» Bounce n Bang: Physics puzzler
Thu May 02, 2024 11:39 am by ali001
» AIChatSY - AIChatbot Assistant
Wed May 01, 2024 10:48 am by ali001
» Storybook Magic App
Tue Apr 30, 2024 7:06 pm by ali001
» Flower Book Match3 Puzzle Game
Tue Apr 30, 2024 12:17 pm by ali001
» Avian Influenza Symptom in Chickens "Bird Flu H5N1 Virus" Vet learning materials, Poultry Farming
Sat Apr 27, 2024 9:57 am by Ibad Khan Buledi